Successful Cost Reduction Program
The company successfully implemented a cost-reduction program, completed in Q4 2024, which stabilized the business and positioned it for positive cash flow from operations.
Strategic Investment by Novel Innovations
IRIDEX received a strategic investment from Novel Innovations, strengthening the balance sheet with $10 million and an option for an additional $10 million. The investment was made at a significant premium, reflecting the strategic nature and potential value of IRIDEX.
Revenue Growth and Improved Financial Performance
IRIDEX reported year-over-year revenue growth in Q4 2024, with revenue increasing to $12.7 million, up from $12.5 million in the prior year. The gross margin improved to 44.0% from 39.2% in the previous year, and the company achieved positive adjusted EBITDA for the first time in recent history.
Increased Sales of Cyclo G6 Glaucoma Products
Sales of the Cyclo G6 glaucoma product family increased by 9%, with 13,300 probes sold compared to 12,700 in the prior year, and 47 laser systems sold compared to 35 in the same quarter of the prior year.